viiv_gsk_pfizer_david_redfern

David Redfern appointed ViiV chairman

pharmafile | February 28, 2011 | Appointment | Research and Development, Sales and Marketing |ย ย David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketingย 

David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.

He is currently chief strategy officer at GSK, a role he will continue to hold, and takes over from current chairman Julian Heslop who retires on 1 April.

โ€œDavid played a significant role in the creation of ViiV Healthcare and brings his extensive depth of knowledge of the pharmaceutical industry to the Boardโ€ said Julian Heslop. 

Advertisement

David was appointed GSKโ€™s chief strategy officer in May 2008 and is responsible for proactive exploration of new business opportunities and strategic planning.

He previously served as senior VP for Northern Europe with responsibility for managing GSK’s pharmaceutical business, and prior to that was the senior VP and chief financial officer of Pharma Europe.

He also held overall responsibility for the European HIV business from 2006 to 2008.

Related Content

GSKโ€™s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSKโ€™s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Dรผsseldorf with …

NICE recommends Pfizerโ€™s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21stย May 2025ย โ€“ย Pfizer Ltd announced today that the National Institute for Health and Care …

The Gateway to Local Adoption Series

Latest content